Trade

with

Ligand Pharmaceuticals Inc
(NASDAQ: LGND)
AdChoices
53.43
-0.72
-1.33%
After Hours :
-
-
-

Open

54.15

Previous Close

54.15

Volume (Avg)

69.46k (435.63k)

Day's Range

53.21-54.29

52Wk Range

41.99-80.42

Market Cap.

1.12B

Dividend Rate ( Yield )

-

Beta

1.55

Shares Outstanding

20.78M

P/E Ratio (EPS)

153.85 (0.35)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 48.97M

    • Net Income

    • 11.42M

    • Market Cap.

    • 1.12B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 13.85

    • PEG (Price/Earnings Growth) Ratio

    • 0.69

    • Beta

    • 1.55

    • Forward P/E

    • 22.27

    • Price/Sales

    • 21.41

    • Price/Book Value

    • 17.54

    • Price/Cash flow

    • 59.17

      • EBITDA

      • 17.61M

      • Return on Capital %

      • 7.54

      • Return on Equity %

      • 14.54

      • Return on Assets %

      • 7.54

      • Book Value/Share

      • 3.09

      • Shares Outstanding

      • 20.78M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 86.83

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 1.98

        • Cashflow Estimate

        • 3.04

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -56.90

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 12.39

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 86.20

            • 82.75

            • Pre-Tax Margin

            • 13.67

            • 39.38

            • Net Profit Margin

            • 13.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 92.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -18.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 1.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.54

              • 2.92

              • Quick Ratio

              • 1.37

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.56

              • 2.21

              • Book Value/Share

              • 3.09

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 142.86

                • 243.90

                • P/E Ratio 5-Year High

                • 229.81

                • 634.30

                • P/E Ratio 5-Year Low

                • 23.26

                • 124.82

                • Price/Sales Ratio

                • 19.88

                • 9.29

                • Price/Book Value

                • 16.26

                • 8.39

                • Price/Cash Flow Ratio

                • 59.17

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 14.54

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 7.54

                    (2.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 12.27

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 376.10k

                  • 117.08k

                  • Inventory Turnover

                  • 4.86

                  • 1.48

                  • Asset Turnover

                  • 0.54

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  14.94M
                  Operating Margin
                  30.51
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  59.17
                  Ownership

                  Institutional Ownership

                  98.05%

                  Top 10 Institutions

                  51.19%

                  Mutual Fund Ownership

                  48.55%

                  Float

                  77.39%

                  5% / Insider Ownership

                  6.49%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,270,943

                  • -8.14

                  • 6.12

                  • PowerShares Dynamic Pharmaceuticals Port

                  •  

                    787,841

                  • 0.00

                  • 4.37

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    382,366

                  • 0.57

                  • 1.98

                  • RS Select Growth Fund

                  •  

                    356,370

                  • -0.34

                  • 1.72

                  • iShares Russell 2000 (AU)

                  •  

                    312,145

                  • -1.81

                  • 1.62

                  • SPDR® S&P Biotech ETF

                  •  

                    304,293

                  • -9.83

                  • 1.58

                  • Vanguard Total Stock Mkt Idx

                  •  

                    294,835

                  • 2.81

                  • 1.42

                  • RS Small Cap Growth Fund

                  •  

                    273,800

                  • 7.92

                  • 1.32

                  • iShares Nasdaq Biotechnology

                  •  

                    270,135

                  • -0.24

                  • 1.40

                  • Vanguard Extended Market Index Fund

                  •  

                    176,172

                  • -8.89

                  • 0.85

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    1,718,486

                  • +3.23%

                  • 8.27

                  • Bvf Inc

                  •  

                    1,408,599

                  • -46.36%

                  • 6.78

                  • RS Investment Management Co. LLC

                  •  

                    1,392,185

                  • +13.88%

                  • 6.70

                  • BlackRock Fund Advisors

                  •  

                    1,298,901

                  • -4.14%

                  • 6.25

                  • Knott David M

                  •  

                    1,249,766

                  • 0.00%

                  • 6.01

                  • Vanguard Group, Inc.

                  •  

                    1,043,782

                  • +6.05%

                  • 5.02

                  • Blair William & Co

                  •  

                    843,711

                  • -9.92%

                  • 4.06

                  • State Street Corp

                  •  

                    571,984

                  • -2.97%

                  • 2.75

                  • Cardinal Capital Management Llc

                  •  

                    568,199

                  • -3.24%

                  • 2.73

                  • Invesco PowerShares Capital Mgmt LLC

                  •  

                    545,116

                  • -14.79%

                  • 2.62

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company...more has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Pro...moremacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.lessless

                  Key People

                  Mr. John L. Higgins

                  CEO/President/Director

                  Dr. John W. Kozarich,PhD

                  Chairman of the Board/Director

                  Nishan de Silva

                  Vice President, Divisional/CFO

                  Mr. Matthew W. Foehr

                  COO/Executive VP

                  Charles S. Berkman

                  Vice President/General Counsel/Secretary

                  • Ligand Pharmaceuticals Inc

                  • 11119 North Torrey Pines Road

                  • La Jolla, CA 92037

                  • USA.Map

                  • Phone: +1 858 550-7500

                  • Fax: -

                  • ligand.com

                  Incorporated

                  1987

                  Employees

                  20

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: